There is some legitimate concern though what will

There is some legitimate concern though what will happen if any deal should take much longer to materialise than year end: let's say we'd need to raise cash until approval in Q2 (worst case). Would they be able to sell 150m more shares IF the SP shouldn't reflect BLA submission, if cancer interim results take longer than anticipated...

And pointing out where NP has gone astray, by insinuating things to shareholders he knew wouldn't happen and by dropping the ball on the stability data is not hating, but pointing out facts that are needed to paint the whole picture of CYDY, any potential investor should know about this. There is a reason for the SP being at .38. It's not that anyone here is bearish on the company as a whole, since most acknowledge Nader's hard and successful efforts to bring leronlimab through approval and that he has brought persons much more qualified and prolific. But it would be the duty of the BOD, for instance, to keep Nader in check as to his communication strategy. And they could also become nore active as to financing.

And given all this it is not surprising that many have learned to be suspicious of Nader's promises, which would have been avoidable if we had communicated more efficiently and clearly in the past.

Bottom line is that it is impossible to infer a plausible timeline from their communication ("any day now" can mean 7 months, "6 weeks" apparently end of year, "golden quarter" + 3 years).

VERY VERY hopeful to see something definitive inked in October and get a solution for the financing for the rest of the year today, as promised

(And btw, no one in their right mind would have voted for an increase if Nader had pointed out before the vote that they didn't manage to put some 700mg vials in the fridge).